TCAF1 and prostate cancer: Furthermore, as cancer-specific hypermethylation was detectable in DNBs, our results suggest that RHCG-TCAF1 has the potential to improve the accuracy of prostate cancer prognosis at the time of diagnosis, where only pre-operative clinicopathological parameters are available (biopsy-based GS, clinical tumor stage, and pre-operative PSA).